Effects of single or combined histamine H1-receptor and leukotriene CysLT1-receptor antagonism on nasal adenosine monophosphate challenge in persistent allergic rhinitis

British Journal of Clinical Pharmacology

Volumn 57, Issue 6, 2004, Pages 714-719

  Lee, Daniel K C ^a   Jackson, Catherine M ^b   Soutar, Patricia C ^a   Fardon, Thomas C ^a   Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Adenosine monophosphate; Fexofenodine; Histamine H1 receptor antagonist; Leukotriene CysLT1 receptor antagonist; Montelukast; Nasal challenge; Peak nasal inspiratory flow; Persistent allergic rhinitis

Indexed keywords

ADENOSINE PHOSPHATE; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PLACEBO;

ADULT; ALLERGIC RHINITIS; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MALE; NOSE AIRFLOW; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ACETATES; ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; NUCLEOTIDASES; QUINOLINES; RECEPTORS, HISTAMINE H1; RHINITIS, ALLERGIC, PERENNIAL; TERFENADINE; TREATMENT OUTCOME;

EID: 2042426642     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02072.x     Document Type: Article

References (27)

1. Malm L, Gerth vW, Bachert C. Guidelines for nasal provocations with aspects on nasal patency, airflow, and airflow resistance. International Committee on Objective Assessment of the Nasal Airways, International Rhinologic Society. Rhinology 2000; 38: 1-6.
2. Litvyakova LI, Baraniuk JN. Nasal provocation testing: a review. Ann Allergy Asthma Immunol 2001; 86: 355-64.
3. Wilson AM, Sims EJ, Orr LC, Robb F, Lipworth BJ. An evaluation of short-term corticosteroid response in perennial allergic rhinitis using histamine and adenosine monophosphate nasal challenge. Br J Clin Pharmacol 2003; 55: 354-9.
4. Lee DK, Gray RD, Lipworth BJ. Adenosine monophosphate bronchial provocation and the actions of asthma therapy. Clin Exp Allergy 2003; 33: 287-94.
5. De Meer C, Heederik D, Postma DS. Bronchial responsiveness to adenosine 5′-monophosphate (AMP) and methacholine differ in their relationship with airway allergy and baseline FEV (1). Am J Respir Crit Care Med 2002; 165: 327-31.
6. van den Berge M, Kerstjens HA, Meijer RJ et al. Corticosteroid-induced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in airway inflammation than improvement in the PC20 of methacholine. Am J Respir Crit Care Med 2001; 164: 1127-32.
7. van den Berge M, Meijer RJ, Kerstjens HA et al. PC(20) adenosine 5′-monophosphate is more closely associated with airway inflammation in asthma than PC(20) methacholine. Am J Respir Crit Care Med 2001; 163: 1546-50.
8. van den Berge M, Kerstjens HA, Postma DS. Provocation with adenosine 5′-monophosphate as a marker of inflammation in asthma, allergic rhinitis and chronic obstructive pulmonary disease. Clin Exp Allergy 2002; 32: 824-30.
9. Holgate ST. Adenosine provocation: a new test for allergic type airway inflammation. Am J Respir Crit Care Med 2002; 165: 317-8.
10. Meltzer EO, Malmstrom K, Lu S et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 2000; 105: 917-22.
11. Nayak AS, Philip G, Lu S, Malice MP, Reiss TF. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002; 88: 592-600.
12. Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108: S147-S334.
13. Lee DK, Carstairs IJ, Haggart K, Jackson CM, Currie CP, Lipworth BJ. Butterbur, a herbal remedy, attenuates adenosine monophosphate induced nasal responsiveness in seasonal allergic rhinitis. Clin Exp Allergy 2003; 33: 882-6.
14. Wilson AM, Sims EJ, Robb F, Cockburn W, Lipworth BJ. Peak inspiratory flow rate is more sensitive than acoustic rhinometry or rhinomanometry in detecting corticosteroid response with nasal histamine challenge. Rhinology 2003; 41: 16-20.
15. Sims EJ, Wilson AM, White PS, Gardiner Q, Lipworth BJ. Short-term repeatability and correlates of laboratory measures of nasal function in patients with seasonal allergic rhinitis. Rhinology 2002; 40: 66-8.
16. Togias A. Systemic cross-talk between the lung and the nose. Am J Respir Crit Care Med 2001; 164: 726-7.
17. Lee DK, Haggart K, Currie GP, Anderson SD, Lipworth BJ. The effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis. Br J Clin Pharmacol 2003; 55: 639-42.
18. Anderson SD, Brannan J, Spring J et al. A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol. Am J Respir Crit Care Med 1997; 156: 758-65.
19. Koskela H, Di Sciascio MB, Anderson SD et al. Nasal hyperosmolar challenge with a dry powder of mannitol in patients with allergic rhinitis. Evidence for epithelial cell involvement. Clin Exp Allergy 2000; 30: 1627-36.
20. Roquet A, Dahlen B, Kumlin M et al. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med 1997; 155: 1856-63.
21. Simons FE, Johnston L, Gu X, Simons KJ. Suppression of the early and late cutaneous allergic responses using fexofenadine and montelukast. Ann Allergy Asthma Immunol 2001; 86: 44-50.
22. Philip G, Malmstrom K, Hampel FC et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002; 32: 1020-8.
23. Pullerits T, Praks L, Ristioja V, Lotvall J. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109: 949-55.
24. Wilson AM, Sims EJ, Orr LC et al. Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2001; 87: 344-9.
25. Wilson AM, Orr LC, Sims EJ, Lipworth BJ. Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin Exp Allergy 2001; 31: 61-8.
26. Creticos PS, Peters SP, Adkinson NF Jr et al. Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N Engl J Med 1984; 310: 1626-30.
27. Bisgaard H, Olsson P, Bende M. Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy 1986; 16: 289-97.